Enliven Therapeutics

Yahoo Finance • 3 months ago

Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst

Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst HC Wainwright initiated coverage on Enliven Therapeutics, Inc. (NASDAQ:ELVN) and noted the company as an emerging biotech compa... Full story

Mentioned:

• AZN
• BMY
• NVS
• PFE

Yahoo Finance • last year

Enliven Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update

Company on track to deliver initial proof of concept data for ELVN-001 and ELVN-002 in 2024 Strong balance sheet, closing the quarter with $263 million in cash, cash equivalents and marketable securities, which is expected to provide cash... Full story